华森制药实控人方近1年减持2088万股 套现约3.5亿元

Core Viewpoint - The announcement from Huason Pharmaceutical (002907.SZ) reveals significant shareholding changes involving its controlling shareholder Chengdu Dijiang and associated parties, indicating a planned reduction in their stake in the company [1][2]. Shareholding Changes - Prior to the changes, the information disclosure obligors collectively held 292,317,525 shares, representing 70.00% of Huason Pharmaceutical's total share capital [2]. - From January 23, 2025, to January 13, 2026, Chengdu Dijiang plans to reduce its holdings by 14,373,176 shares (3.44% of total share capital), while You Hongtao and the Tiancheng Tianli No.1 Private Fund will reduce their holdings by 5,965,965 shares (1.43%) and 540,780 shares (0.13%) respectively [2]. Financial Impact - The weighted average price of Huason Pharmaceutical shares during the reduction period is reported at 16.894 yuan per share, leading to an estimated total reduction amount of approximately 352.75 million yuan [2]. Future Reduction Plans - The information disclosure obligors have plans for further share reductions within the next 12 months, with You Hongtao intending to sell up to 6,649,826 shares (1.59%) and the Tiancheng Tianli No.1 Fund planning to reduce its holdings by up to 5,878,000 shares (1.41%) [3][4]. - The total planned reduction from these parties is capped at 12,527,826 shares, which is 3% of Huason Pharmaceutical's total share capital [4].